• br Materials and Methods br

  2024-01-13

  

  Materials and Methods Author Contributions Conflicts of Interest Acknowledgments This study was funded by the NIH Common Fund (UH2TR000943) through the Office of Strategic Coordination/Office of the NIH Director, an NCI/NIH grant (1R21CA199050), the MD Anderson Cancer Center support gran

• br Conflict of interest br Introduction Ovarian cancer

  2024-01-13

  

  Conflict of interest Introduction Ovarian cancer is the most lethal gynecological malignancy, and ranks as the fifth leading cause of cancer death among women. The American Cancer Society estimates that about 22,280 new ovarian cancer cases and 14,240 deaths will occur in the United States in

• and LO are members of

  2024-01-13

  

  5- and 12/15-LO are members of the lipoxygenase family that convert arachidonic UNC 3230 into lipid mediators such as leukotriene B4 (LTB) and 12()-hydroxyeicosatetraenoic acid (HETE) and 15()-HETE, respectively. Evidence from several in vitro and in vivo studies has shown that activation of the 5-

• br Perspective AA LA and other PUFAs and

  2024-01-13

  

  Perspective AA, LA and other PUFAs and their lipid metabolites play an important role in human diseases. 12/15-LOX which is the metabolic enzyme of them plays an important role in the pathogenesis-related diseases such as atherosclerosis, diabetic nephropathy, neurological diseases and other path

• In the nineties we knew that

  2024-01-13

  

  In the nineties we knew that (-)baclofen was the stereo-selective ligand for the GABAB receptor which had been recognised by Norman Bowery as a receptor for GABA, which was different from the GABAA receptor (Hill and Bowery, 1981). GABAB receptor antagonists were also synthesised and made available

• br Introduction Heart failure HF is a

  2024-01-12

  

  Introduction Heart failure (HF) is a chronically progressive disease and one of the most important causes of morbidity and mortality worldwide despite recent improvements in its treatment [1], [2], [3]. The mortality and morbidity benefits of angiotensin converting enzyme inhibitor (ACEI) are wel

• No starting dose adjustment is

  2024-01-12

  

  No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad

• In the present study a splice acceptor site

  2024-01-12

  

  In the present study, a splice acceptor site mutation (c.1769-1G > C) was identified in AR gene from patients with CAIS. The c.1769-1G > C mutation results in replacement of the normal sequence (CAG/G) with a new sequence (CAC/G) at the splice acceptor site of intron 2. In the splice acceptor site r

• br Conclusions In summary we report a novel preliminary find

  2024-01-12

  

  Conclusions In summary, we report a novel preliminary finding of a potential racial difference in the association of Cd-content and AR expression in prostate cancer that will need to be confirmed in larger studies. Although the association of Cd and AR protein expression is not strong in tumor ti

• Our in vitro data show that CyaA does

  2024-01-12

  

  Our in vitro data show that CyaA does not play a critical role in the bacterial adherence to mammalian cells. This observation is in contrast to previous studies that reported a role for CyaA in FHA-mediated adherence of B. pertussis bacteria to the respiratory epithelial Iodoacetyl-LC-Biotin [37,3

• HS-173 Although the immobilization by histidine tag exhibits

  2024-01-12

  

  Although the immobilization by histidine tag exhibits effectiveness in oriented enzyme immobilization, it still faces some challenges [31]. On one hand, some unnecessary metal-binding proteins that interfere with the combination between the target protein and the supports or the additional interacti

• br Results br Discussion Utilizing a

  2024-01-12

  

  Results Discussion Utilizing a proteomic approach, we identified HSP90β as a protein that becomes associated with surface AChR in agrin-stimulated muscle cells. We demonstrate that HSP90β does not interact with the AChR directly; instead, via direct interaction with rapsyn, HSP90β becomes asso

• The nAChR has been considered an interesting potential targe

  2024-01-12

  

  The α7 nAChR has been considered an interesting potential target for numerous therapeutic indications over the last two decades, with GTS-21 one of the first candidates proposed for Alzheimer's disease [2], [3], [23]. Unfortunately, although many α7-selective agonists have been developed [21], none

• Nevertheless though the LO pathway dictates

  2024-01-12

  

  Nevertheless, though the 5-LO pathway dictates the production of lipid mediators with opposite roles in the immune reactions, like LTs and LXA4 [32], our results seemed to corroborate others that pointed to LTB4 as an outstanding mediator involved in persistent and chronic inflammatory skin diseases

• A promising target that is

  2024-01-12

  

  A promising target that is involved in the biosynthesis of the precursor LTA4 is the 5-LO-activating protein (FLAP), which in vivo is seemingly indispensable for LT formation [8], [9]. FLAP, a member of the MAPEG family (membrane-associated proteins in eicosanoid and glutathione metabolism), is an i

16541 records 219/1103 page Previous Next First page 上5页 216217218219220 下5页 Last page